Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

NCT00841763 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3647

Enrollment

INDUSTRY

Sponsor class

Conditions

Pandemic Influenza Disease

Interventions

BIOLOGICAL: Placebo (PL)
BIOLOGICAL: Trivalent influenza virus vaccine (TIV)
BIOLOGICAL: Adjuvanted monovalent influenza virus vaccine (aH5N1)
BIOLOGICAL: Adjuvanted trivalent influenza virus vaccine (aTIV)

Sponsor

Novartis

Collaborators

[object Object]